November Question of the Month

Which of the following will be the most limiting factor for manufacturers to use the FDA’s guidance documents in the development of “complex generic drugs”?

Limited time and resources of the FDA: 0%

High cost of developing complex generic drugs: 25%

Low return on investment: 25%

Complex clinical testing to prove equivalence: 50%

None of these: 0%